• Bile Acid Metabolism Subtypes Reveal Immune Markers in CRC

  2026-06-02

  Feng et al. (2026) introduce a novel integrative molecular subtyping of colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers of immune dysfunction and prognosis. Their multi-cohort validation provides new avenues for patient stratification and insights into the tumor immune microenvironment, holding translational relevance for biomarker-driven research.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor M

  2026-06-01

  This study introduces a novel patient-derived gastric cancer assembloid model integrating matched tumor organoids with autologous stromal cell subpopulations. The approach significantly advances preclinical research by more accurately recapitulating tumor heterogeneity and drug response, enabling deeper investigation of therapeutic resistance and personalized medicine strategies.

• Lymphodepleting Chemotherapy Boosts T Cell Therapy via Antig

  2026-06-01

  Sagie et al. (2025) demonstrate that lymphodepleting chemotherapy, including regimens containing DNA synthesis inhibitors, synergizes with neoantigen-directed T cell therapies by enhancing tumor antigen presentation. The study establishes a mechanistic link between immunoproteasome activation, increased HLA-I expression, and improved T cell-mediated tumor eradication, offering actionable insights for optimizing adoptive cell therapy protocols.

• FPH1 (BRD-6125): Unlocking Hepatocyte Proliferation in Cultu

  2026-05-31

  FPH1 (BRD-6125) empowers scalable, donor-independent expansion of functional human hepatocytes, streamlining workflows from iPSC differentiation to drug metabolism testing. Explore protocol enhancements and troubleshooting strategies that maximize albumin secretion and CYP3A4 activity, as validated by both bench studies and emerging gene regulation techniques.

• RIPA Lysis Buffer (Strong, without inhibitors): Technical Us

  2026-05-30

  RIPA Lysis Buffer (Strong, without inhibitors) enables robust extraction of proteins from animal cells and tissues by combining strong detergent action with user-controlled addition of inhibitors. It is suitable for workflows requiring efficient membrane solubilization but is not recommended when immediate protease or phosphatase inhibition is essential or if processing delays are expected.

• Cell Tumbling Regulates Stem Cell Fate via Nuclear Mechanotr

  2026-05-29

  The referenced study introduces 'cell tumbling' as a rapid, three-dimensional cellular movement in hydrogels that significantly enhances stem cell differentiation through nuclear mechanotransduction. This work reframes our understanding of how dynamic physical interactions within the cellular microenvironment can dictate lineage commitment, with broad implications for designing advanced biomaterials and tissue engineering strategies.

• Sorafenib (BAY-43-9006): Multikinase Inhibitor for Oncology

  2026-05-29

  Sorafenib (BAY-43-9006) is a multikinase inhibitor that targets Raf, VEGFR-2, and PDGFRβ, exhibiting nanomolar potency in vitro. It is widely applied in cancer biology research for studying antiangiogenic and antiproliferative mechanisms. Recent evidence also validates Sorafenib as a robust host-directed antiviral candidate.

• Macrophage Extracellular Vesicle miR-660 Drives Breast Cance

  2026-05-28

  This study elucidates how tumor-associated macrophages (TAMs) promote breast cancer progression through extracellular vesicle-enclosed microRNA-660, which targets KLHL21 to activate NF-κB signaling. These findings highlight a specific molecular pathway that may inform future strategies for targeting metastasis in breast cancer.

• Topotecan HCl: Mechanistic Insights in DNA Damage and Tumor

  2026-05-28

  Explore how Topotecan HCl, a topoisomerase 1 inhibitor, advances cancer research by inducing DNA damage and apoptosis in tumor cells. This article uniquely connects mechanistic details to DNA repair vulnerabilities, providing advanced insight for translational assay design.

• CCG-1423: RhoA Inhibitor Workflows for Cancer and Viral Path

  2026-05-27

  CCG-1423 redefines experimental precision in dissecting RhoA/ROCK signaling, enabling targeted investigation of cancer cell invasion and viral entry mechanisms. With APExBIO’s high-purity formulation, researchers achieve robust results in complex cell-based assays and advanced apoptosis workflows.

• Propidium Iodide: Quantitative Insights for Cancer Cell Viab

  2026-05-27

  Discover how Propidium iodide, a DNA intercalating dye, enables robust, quantitative cell viability and cell cycle analysis, with a special focus on telomere maintenance in cancer cells. This article delivers unmatched scientific depth and practical guidance for advanced researchers.

• Gastrin I (human): Assay Optimization and Organoid Integrati

  2026-05-26

  Explore how human Gastrin I peptide enables robust gastric acid secretion pathway research and advanced gastrointestinal physiology studies. This article uniquely bridges peptide assay optimization with the integration of hiPSC-derived organoid models.

• FAST Enables Food-Grade Nanoparticles for Enhanced Nutraceut

  2026-05-26

  The referenced study introduces Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade method for preparing stable, bioavailable nutraceutical nanoparticles. This innovation addresses the longstanding challenge of poor solubility and bioavailability for key bioactives, and is positioned to advance scalable, regulatory-compliant supplement delivery.

• Firefly Luciferase mRNA (ARCA, 5-moUTP): Next-Gen Assay Reli

  2026-05-25

  Explore how Firefly Luciferase mRNA (ARCA, 5-moUTP) advances assay reliability and translational research through biophysical design and cutting-edge mRNA loading strategies. Discover unique insights on optimizing bioluminescent reporter assays for robust, reproducible results.

• High Viscosity Drives Chemoresistance via P-gp Upregulation

  2026-05-25

  This study demonstrates that high extracellular fluid viscosity in the tumor microenvironment promotes chemoresistance by activating a mechanotransduction cascade that upregulates P-glycoprotein (P-gp). The findings clarify a mechanical basis for drug resistance, highlighting new potential therapeutic strategies to enhance chemotherapy efficacy.

15957 records 7/1064 page Previous Next First page 上5页 678910 下5页 Last page